Intercept Pharma's hopes of getting its non-alcoholic steatohepatitis (NASH) therapy obeticholic acid (OCA) in the US may have taken another dive, after it flunked a phase 3 trial. Shares in the ...
GSK has signed an eleventh-hour agreement to give Alfasigma rights to its primary biliary cholangitis (PBC) therapy linerixibat, which is under regulatory review in most major pharma markets worldwide ...
The type of graph you use depends on the type of data you want to represent. In a bar chart, the height of the bar shows the frequency of the result. As the height of bar represents frequency, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results